FDA Approves Mavacamten under Brand Name Camzyos Published on May 8, 2022July 4, 2022 by hcmbeat2 Comments At long last, there is a FDA approved drug specifically intended for the treatment of hypertrophic cardiomyopathy. After several years of testing, and based on the results of the groundbreaking EXPLORER-HCM trial, Bristol Myers Squibb’s new drug mavacamten, being marketed under the brand name Camzyos, is now available to HCM patients. Continue reading “FDA Approves Mavacamten under Brand Name Camzyos” → Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to email a link to a friend (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Pinterest (Opens in new window)MoreClick to print (Opens in new window)Like this:Like Loading...
HCM Beat 